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Background: Completion lymph node dissection (CLND) is considered the standard of care
in melanoma patients found to have sentinel lymph node (SLN) metastasis. However, the
therapeutic utility of CLND is not known. The natural history of patients with positive SLNs
who do not undergo CLND is undefined. This multi-institutional study was undertaken to
characterize patterns of failure and survival rates in these patients and to compare results with
those of positive-SLN patients who underwent CLND.
Methods: Surgeons from 16 centers contributed data on 134 positive-SLN patients who did
not undergo CLND. SLN biopsy was performed by using each institutions established pro-
tocols. Patients were followed up for recurrence and survival.
Results: In this study population, the median age was 59 years, and 62% were male. The
median tumor thickness was 2.6 mm, 77% of tumors had invasion to Clark level IV/V, and
33% of lesions were ulcerated. The primary melanoma was located on the extremities, trunk,
and head/neck in 45%, 43%, and 12%, respectively. The median follow-up was 20 months. The
median time to recurrence was 11 months. Nodal recurrence was a component of the first site
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of recurrence in 20 patients (15%). Nodal recurrence–free survival was statistically insignifi-
cantly worse than that seen in a contemporary cohort of patients who underwent CLND.
Disease-specific survival for positive-SLN patients who did not undergo CLND was 80% at 36
months, which was not significantly different from that of patients who underwent CLND.
Conclusions: This study underscores the importance of ongoing prospective randomized
trials in determining the therapeutic value of CLND after positive SLN biopsy in melanoma
patients.
Key Words: Melanoma—Sentinel lymph node biopsy—Completion lymphadenectomy—
Recurrence—Survival.
Sentinel lymph node (SLN) biopsy has become
widely accepted as a staging procedure for patients
with primary cutaneous melanoma. SLN biopsy is a
highly accurate procedure that uses well-character-
ized lymphatic mapping techniques. Histopathologic
studies have validated the diagnostic utility of SLN
biopsy, thus proving that the SLN accurately predicts
the status of the regional nodal basin.1 The presence
of SLN metastasis has also been shown to be the
most important prognostic factor in terms of clinical
outcome in patients with clinical stage I or II mela-
noma.2
When SLN metastases are found, the current
standard of care is completion lymph node dissec-
tion (CLND). Approximately 15% to 20% of pa-
tients are found to have additional disease in the
CLND specimen. Prior studies have attempted to
define uniform predictors of metastasis in non-SLNs
to determine which patients are at high risk of
further disease and should have CLND. Likewise,
CLND could be abandoned if patients who have an
exceedingly low risk of non-SLN metastasis could
be reliably identified. Because accurate predictive
factors have yet to be identified, CLND continues
to be routinely performed in patients found to have
a positive SLN.2–6
However, the therapeutic utility of CLND after
positive SLN biopsy is unknown, both in terms of
regional control and disease-specific survival (DSS).
Very little is known about the natural history of pa-
tients with positive SLNs who do not undergo CLND.
Nodal recurrences have been reported in up to 10% of
patients after CLND for occult metastasis detected by
SLN biopsy.7 The risk of developing same-basin no-
dal recurrence if positive SLN biopsy is not followed
by CLND has yet to be determined. Results from
prospective randomized trials of elective lymph node
dissection (ELND) have failed to demonstrate a sur-
vival advantage over observation and therapeutic
lymph node dissection for patients with clinical stage I
or II melanoma. In most of these studies, nodal basin
recurrence rates were quite similar to the incidence of
involved lymph nodes found at ELND. Because SLN
biopsy potentially spares 80% of patients a negative
ELND, a survival benefit may be seen given a more
select population of patients undergoing CLND.
The potential benefit of CLND in the context of
node positive selective lymphadenectomy is currently
being investigated in the Multicenter Selective Lym-
phadenectomy Trial II, a large prospective random-
ized study that is open and actively accruing. Patients
with positive SLNs are randomized to immediate
CLND or close nodal observation. The observation
arm of the trial involves interval follow-up and
ultrasound examination of the involved regional no-
dal basin, with CLND if nodal metastases are de-
tected at a later time.
This study represents a multi-institutional collab-
oration undertaken to characterize the natural his-
tory of patients with SLN metastases who did not
undergo CLND. Aims of the study were to determine
patterns of recurrence and to examine the effect on
DSS of foregoing CLND. The experience of a con-
temporary cohort of patients from Memorial Sloan-
Kettering Cancer Center (MSKCC) with positive
SLNs who had CLND was used as a standard of
comparison for patterns of recurrence and survival.
METHODS
We contacted 26 investigators from high-volume
melanoma institutions regarding participation in this
study. Investigators from 21 centers expressed inter-
est in participating. Ultimately, patient data from 16
institutions were provided for analysis. Standardized
data were requested for consecutive patients with
SLN metastasis who did not undergo CLND,
including patient, tumor, and SLN characteristics
and follow-up information. Data were collected un-
der the auspices of each centers institutional review
board guidelines.
SLN biopsy was performed according to the
individual surgeons preferred mapping techniques.
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Harvested SLNs were examined by using each
institutions established histopathologic protocols
for serial sectioning, hematoxylin and eosin staining,
and immunohistochemistry (IHC) staining. Central-
ized pathology review was not performed. Microm-
etastatic disease was defined as detection of
metastasis by histologic examination only. Patients
with metastases found only with reverse transcrip-
tase-polymerase chain reaction were not included in
this analysis.
Reasons why CLND was not performed were
elicited as part of the data collection. Data regarding
other modalities of treatment, such as interferon alfa-
2b or vaccine protocols, were not captured. Only
patients with adequate prospective follow-up were
eligible for inclusion in this study. Patients who re-
fused CLND and did not return for follow-up were
not included in this study. We allowed investigators
to report patients seen as referrals after positive SLN
biopsy at outside institutions. Patients with positive
SLN who did not have CLND, but who presented to
participating centers for treatment of recurrence,
were excluded from analysis.
Clinical follow-up intervals were at the discretion
of the individual surgeon. Data regarding methods of
follow-up and subsequent detection of recurrent dis-
ease were not collected for this study. Each patients
clinical course was reported according to the site of
disease recurrence, if any, and disease status at the
time of last follow-up.
Recurrences were characterized as locoregional,
defined as local or in-transit disease; nodal, defined as
recurrences in the mapped basin; or systemic, defined
as disease in all other sites. The recurrence rates and
survival outcomes for patients with positive SLNs
who did not undergo subsequent CLND were com-
pared with results from a contemporary cohort of
patients from MSKCC, the organizing center for this
study, who had positive SLN biopsy followed by
CLND. These patients were identified from a pro-
spectively maintained database and represent con-
secutive patients treated between March 1992 and
September 2004.
Statistical analyses were performed with SPSS
software, version 12 (SPSS, Inc., Chicago, IL).
Comparisons were made by using v2 analysis or
Students t-test, and estimated survival rates were
calculated by the Kaplan-Meier method. The influ-
ence of CLND on outcome was evaluated by com-
paring the collected series with the MSKCC cohort
and subjecting the combined group of patients to
multivariable analysis with Cox regression analysis.
P < .05 was considered significant.
RESULTS
The study population included 134 patients from 16
institutions with histologically positive SLNs who did
not undergo CLND. It is interesting to note that
investigators from four institutions indicated that they
had no patients who elected observation after positive
SLN biopsy. Clinicopathologic characteristics,
including patient, tumor, and SLN factors, are listed in
Table 1. In the vast majority of cases, the decision to
forego CLND was made by the patient alone or by the
patient and physician jointly (Table 2). Nearly half of
patients refused CLND. When the decision for nodal
observation was made between the patient and phy-
sician, commonly cited reasons included medical
comorbidities, findings of an interval/in-transit posi-
tive SLN, or enrollment to a clinical trial where nodal
observation was selected.
The median follow-up for the entire group was 20
months. The median time to recurrence was 11
months. For patients without recurrent disease, the
median follow-up was 18 months. Recurrent disease
was reported in 49 (37%) patients. Patterns of first
recurrence are listed in Table 3. In the study popu-
lation, local or in-transit recurrences were seen as
sites of first recurrence in seven (14%) patients. Sys-
temic disease was seen as a component of initial
recurrence in 51% of patients (25 of 49) who had
recurrences. Recurrent disease in the previously
mapped nodal basin was seen either alone (14 of 134
patients; 10%) or as a component of first recurrence
(20 of 134; 15%). Concomitant presentation with
both nodal and systemic recurrence was reported in
three patients. Of note, one patient presented with
systemic metastases as a site of first recurrence but
later developed a recurrence in the nodal basin.
Among 14 patients with a nodal-only recurrence,
10 underwent successful salvage lymphadenectomy.
Of those patients, four remain free of disease, four
have died of disease, and two were alive with disease
at time of last follow-up. Among the 10 patients who
did not have salvage lymphadenectomy for some
type of nodal recurrence, 5 were alive with disease
and 5 were dead of disease at the last reported
follow-up.
The estimated nodal recurrence–free survival for
positive-SLN patients who did not undergo CLND,
as calculated by the Kaplan-Meier method, is shown
in Fig. 1. Comparison to a contemporary series of
164 melanoma patients with positive SLNs who had
CLND was made by using the prospectively main-
tained melanoma database at MSKCC. The clini-
copathologic characteristics of this group of patients
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from MSKCC with SLN metastasis are largely
comparable to those of the study population
(Table 1), except that the study population had
fewer patients with ulceration of the primary tumor,
a lower proportion of melanoma primary tumors
with invasion to Clark level IV or V (not statistically
significant), and more patients with micrometastatic
disease in the SLN, as detected by IHC. Taking
these tumor and SLN characteristics into account,
the group of patients who underwent CLND seems
to have an overall poorer set of prognostic indica-
tors.
The median follow-up for the MSKCC cohort of
patients was 36 months—somewhat longer than the
20 months in the study group. Patterns of recurrence
are listed in Table 3. The nodal recurrence–free sur-
vival at 36 months was 88% in the MSKCC cohort,
compared with 80% in this study population (Fig. 1).
There was a statistically insignificant trend toward
worse nodal recurrence–free survival when CLND
was not performed (P = .07; log rank).
The estimated DSS in patients with positive SLN
biopsy results is shown in Fig. 2A. The DSS at 3
years was 80%. The overall DSS of patients with
positive SLNs who did not undergo CLND was no
different from that of positive SLN-patients who had
CLND (Fig. 2B), as seen on log-rank analysis
(P = .65).
The results of Cox regression analysis (univariable
and multivariable) of clinicopathologic factors with
respect to nodal recurrence–free survival and DSS are
as seen in Table 4. The two groups of patients were
combined for the purposes of this analysis (n = 298).
Age and tumor thickness were analyzed as continu-
ous variables. Factors included in the multiple co-
variate analysis included significant variables from
the univariate analysis (up to P < .1) and the major
factor of interest in this study (CLND vs. nodal
observation). On multivariable analysis, the only
factor predictive of decreased nodal recurrence--free
survival was age (P = .04), although a trend toward




who did not undergo CLND (n = 134)
MSKCC cohort: SLN+
patients who underwent
CLND (n = 164) P value
Age, y (median) 59 56 .29
Sex
Male 83 (61.9%) 105 (64%) .71
Female 51 (38.1%) 59 (36%)
Tumor thickness, mm (median) 2.6 2.85 .11
Tumor location
Head/neck 16 (11.9%) 14 (8.5%) .62
Trunk 57 (42.5%) 67 (40.9%)
Extremity 60 (44.8%) 80 (48.8%)
Unknown/other 1 (.7%) 3 (1.8%)
Clark level
II 2 (1.5%) 0 .07
III 20 (14.9%) 11 (6.7%)
IV 87 (64.9%) 119 (72.6%)
V 16 (11.9%) 26 (15.9%)
Unknown 9 (6.7%) 8 (4.9%)
Ulceration
Present 44 (32.8%) 82 (50%) .003
Absent 79 (59.0%) 64 (39%)
Unknown/not reported 11 (8.2%) 18 (11%)
Method of disease detection
IHC only (micrometastatic disease) 38 (28%) 15 (9.1%) <.0001
H&E 96 (72%) 149 (90.9%)
Number of positive nodes
Single positive SLN 106 (79%) 117 (71.3%) .13
Multiple positive SLNs 28 (21%) 47 (28.7%)
SLN, sentinel lymph node; CLND, completion lymph node dissection; MSKCC, Memorial Sloan-Kettering Cancer Center; IHC,
immunohistochemistry; H&E, hematoxylin and eosin.
TABLE 2. Reasons CLND was not performed after positive
SLN biopsy results (n = 134)
Reason n (%)
Patient refusal 65 (49)
Patient/physician decision 64 (48)
Unknown 5 (4)
CLND, completion lymph node dissection; SLN, sentinel lymph
node.
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significance was seen for CLND with regard to de-
creased nodal recurrence.
Factors predictive of decreased DSS were increas-
ing age and tumor thickness (P< .001 and P= .002,
respectively). Whether a patient had CLND or nodal
observation after positive SLN biopsy was not a
significant predictor of DSS on either univariable or
multivariable analysis.
DISCUSSION
SLN biopsy is a valuable diagnostic procedure that
is associated with low false-negative rates and highly
accurate staging. Patients with positive SLNs have a
significantly higher risk of recurrence and death than
those without SLN metastasis.2 Because there is no
reliable way to predict the absence of further disease
in the CLND specimen with certainty, the currently
accepted practice is to perform CLND for positive-
SLN patients. However, the therapeutic utility of
CLND and the natural history of positive-SLN
melanoma patients who did not undergo CLND are
unknown. This series reports a multi-institutional
experience of 134 patients who did not undergo
CLND after positive SLN biopsy. A better under-
standing of this group of patients is essential to assess
the importance of ongoing prospective randomized
trials designed to compare observation of involved
nodal basins with CLND.
We found 20 (15%) patients who had nodal
recurrence as a component of their first recurrence.
This is quite similar to the incidence of positive non-
SLNs had these patients undergone CLND. The
median time to recurrence was 11 months. With a
median follow-up of 20 months, we believe that most,
but not all, of the nodal recurrences have been ob-
served.
FIG. 1. Nodal recurrence–free
survival for melanoma patients with
positive sentinel lymph nodes (SLNs;
P = .07; log-rank analysis). CLND,
completion lymph node dissection;
MSKCC, Memorial Sloan-Kettering
Cancer Center.
TABLE 3. Patterns of first recurrence
Variable
Study population: SLN+
patients who did not




Median follow-up (mo) 20 36
Type of recurrence
Locoregional only 7 (14.3%) 29 (34.1%)
Nodal only 14 (28.6%) 12 (14.1%)
Nodal ± locoregional 17 (34.7%) 14 (16.5%)
Nodal as a component 20 (40.8%) 17 (20.0%)
Systemic as a component 25 (51.0%) 42 (49.4%)
SLN, sentinel lymph node; CLND, completion lymph node dissection; MSKCC, Memorial Sloan-Kettering Cancer Center.
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Recurrent disease in the nodal basin after ELND
has been reported in 4% to 16% of patients.8–11
Consistent with the MSKCC cohort, the incidence of
same-basin nodal recurrence after CLND for positive
SLN results in contemporary series from other insti-
tutions range from 2.6% to 12% in the litera-
ture.7,9,12,13 The median time to nodal basin
recurrence after therapeutic lymph node dissections
or after CLND for positive SLN has previously been
reported to be 13 to 14 months.7 When the nodal
recurrence–free survival of the study population was
compared with that of the MSKCC cohort, the
patients who did not undergo CLND demonstrated a
statistically insignificant trend toward poorer nodal
recurrence–free survival. When both groups of pa-
tients were combined for a Cox regression analysis,
CLND (compared with nodal observation) also
demonstrated a statistically insignificant trend to-
ward decreased nodal recurrence (Table 4). Taking
into account the difference in median follow-up (20
vs. 36 months), this trend toward increased nodal
recurrences in the group who did not have CLND
could become statistically significant with longer
follow-up if a few more nodal recurrences are seen.
Twenty patients had nodal recurrence either alone
or as a component of their initial recurrence. Ten of
14 patients in this study with nodal-only recurrence
underwent successful salvage CLND. At time of last
follow-up, four of these patients were alive with no
evidence of disease, and the remaining six were either
alive with disease or dead of disease. It is conceivable
that patients who do not undergo CLND are sub-
jected to a higher risk of subsequent distant recur-
rences. Whether systemic recurrence and death in
these cases are attributable to aggressive tumor
biology or to delayed nodal intervention can be ad-
dressed only by a prospective trial. Four patients with
nodal-only recurrences did not have CLND, and the
reasons for this were not stated. Small numbers pre-
clude extensive analysis, but there is certainly a risk of
extensive nodal basin disease which is difficult to
control with salvage lymphadenectomy.
The DSS for 134 node positive SLN patients who
did not undergo CLND was remarkably similar to
that of 164 node-positive MSKCC patients who
underwent CLND. The 3-year DSS of 74% reported
for MSKCC patients with positive SLNs who had
CLND is similar to other reports in the literature.
According to the experience at the M. D. Anderson
Cancer Center, the 3-year DSS for positive SLN pa-
tients (CLND was performed) was 70% with a med-
ian follow-up of 40 months.2 We compared this study
population with a contemporary series of patients at
MSKCC who had CLND after positive SLN biopsy.
The groups were relatively well matched, but it seems
that the group of positive-SLN patients who had
CLND had more primary lesions with ulceration and
fewer SLNs with micrometastatic disease, thus mak-
ing them a population with a possibly poorer prog-
nosis. The resulting concern would be that the benefit
FIG. 2. (A) Disease-specific survival (DSS) for melanoma patients with positive sentinel lymph nodes (SLNs) who did not undergo
completion lymph node dissection (CLND; present multi-institutional study). The 3-year DSS was estimated at 80%. (B) DSS for mela-
noma patients with positive SLNs who underwent CLND (Memorial Sloan-Kettering Cancer Center cohort). The 3-year DSS was
estimated at 74%. There was no difference in DSS between the two groups (P = .65; log-rank analysis).
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of CLND in reducing recurrences or improving sur-
vival may be mitigated by poorer clinicopathologic
characteristics.
To examine this issue more carefully, a multiple
covariate Cox regression analysis was performed to
examine whether any prognostic factor was signifi-
cantly predictive of DSS. We found that of those
factors more prominent in the group of positive-SLN
patients who underwent CLND, neither the method
of histopathologic detection (hematoxylin and eosin
vs. IHC) nor the presence of ulceration predicted
decreased DSS. As expected, however, increasing age
and tumor thickness were associated with a worse
DSS for the group as a whole. It is clear that
undergoing CLND after positive SLN biopsy is not a
significant predictor of DSS on either univariate or
multivariable analysis.
The findings of this study should not be taken as a
treatise against SLN biopsy. The diagnostic and
prognostic value of SLN biopsy should not be mini-
mized. SLN biopsy is a minimally invasive, highly
accurate staging procedure. The presence of SLN
metastasis is the most important predictor of clinical
outcome in patients with melanoma. No other vari-
able provides the same independent level of prog-
nostic information. If a positive SLN is found, the
currently accepted practice, outside of a clinical
protocol, is CLND. Although this trial was a retro-
spective analysis of a multi-institutional experience of
a highly selected patient population, it is, to date, the
most comprehensive reporting of the patterns of
recurrence and clinical outcomes in patients with
positive SLNs who did not undergo CLND. We re-
port a statistically insignificant trend toward de-
creased nodal recurrence–free survival in the group of
patients who did not undergo CLND but no differ-
ence in overall DSS compared with patients who
underwent CLND.
Clinical equipoise, or the collective uncertainty over
preferred treatment strategies, is the underlying ethical
tenet of randomized clinical trials.14 The results of this
study strongly support the comparative therapeutic
merit, or equivalency, of the observation arm of two
ongoing randomized prospective trials for patients
with SLN metastasis. Results from trials such as the
regional Florida Melanoma Trial or the larger, na-
tional Multicenter Selective Lymphadenectomy Trial
II15 should help answer the question ofwhetherCLND
after positive SLN biopsy affects recurrence or im-
proves survival. Our findings emphasize the impor-
tance of continued accrual to and completion of these
clinical trials.
CONCLUSIONS
For patients with positive SLNs who did not un-
dergo CLND, nodal recurrence was a component of
the first site of recurrence in 15% of patients, and the
3-year DSS was 80%. With a median follow-up of 20
months, nodal recurrence–free survival and DSS seem
similar to those seen in a contemporary cohort of
patients after CLND for positive SLN biopsy. These
findings underscore the importance of ongoing pro-
spective, randomized trials in defining the therapeutic
value of CLND after positive SLN biopsy in mela-
noma patients.
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